Amgen (AMGN): FY24 Q4 earnings call, Feb 4, 2025
No Kalshi or Polymarket word markets were listed for Amgen’s Feb 4, 2025 earnings call (FY24 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
3 matches for “Prolia”; 3 quoted, at least 25 words apart.
…performing well. The Amgen-affiliate business is growing nicely. That's essentially Repatha and Prolia, both products doing well, both products listed on the national reimbursement drug…
…different situations here with XGEVA largely used in the oncology setting and Prolia used in postmenopausal osteoporosis. So the slopes there could be different. But…
…team of account executives that have been calling on our XGEVA and Prolia accounts for many years now. And we are the bone market leader.…
Agents: this page as TSV at /api/v1/appearances/amgen:2025-02-04:earnings_call · words: /api/v1/brief?appearance=amgen:2025-02-04:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP